Pharmaceutical policies: effects of financial incentives for prescribers
TLDR
The effects of pharmaceutical policies using financial incentives to influence prescribers' practices on drug use, healthcare utilisation, health outcomes and costs are determined and pay for performance policies are evaluated.Abstract:
Background Pharmaceuticals, while central to medical therapy, pose a significant burden to health care budgets. Therefore regulations to control prescribing costs and improve quality of care are implemented increasingly. These include the use of financial incentives for prescribers, namely increased financial accountability using budgets and performance based payments. Objectives To determine the effects on drug use, healthcare utilisation, health outcomes and costs ( expenditures) of policies, that intend to affect prescribers by means of financial incentives. Search strategy We searched the following databases and web sites: Effective Practice and Organisation of Care Group Register ( August 2003), Cochrane Central Register of Controlled Trials ( October 2003), MEDLINE ( October 2005), EMBASE ( October 2005), and other databases. Selection criteria Policies were defined as laws, rules, financial and administrative orders made by governments, non- government organisations or private insurers. One of the following outcomes had to be reported: drug use, healthcare utilisation, health outcomes, and costs. The study had to be a randomised or non- randomised controlled trial, interrupted time series analysis, repeated measures study or controlled before-after study evaluating financial incentives for prescribers introduced for a jurisdiction or healthcare system. Data collection and analysis Two review authors independently extracted data and assessed study limitations. Main results Thirteen evaluations of budgetary policies and none of performance based payments met our inclusion criteria. Ten studies evaluated general practice fundholding in the UK, one the Irish Indicative Drug Target Savings Scheme ( IDTSS) and two evaluated German drug budgets for physicians in private practice. The interrupted time series analyses had some limitations. All the controlled beforeafter studies ( all from the UK) had serious limitations. Drug expenditure ( per item and per patient) and prescribed drug volume decreased with budgets in all three countries. Evidence indicated increased use of generic drugs in the UK and Ireland, but was inconclusive on the use of new and expensive drugs. We found no clear evidence of increased health care utilisation and no studies reporting effects on health. Administration costs were not reported. No studies on the effects of performance- based payments or other policies met our inclusion criteria. Authors' conclusions Based on the evidence in this review from three Western European countries, drug budgets for physicians in private practice can limit drug expenditure by limiting the volume of prescribed drugs, increasing the use of generic drugs or both. Since the majority of studies included were found to have serious limitations, these results should be interpreted with care.read more
Citations
More filters
Journal ArticleDOI
Systematic review: Effects, design choices, and context of pay-for-performance in health care.
Pieter Van Herck,Delphine De Smedt,Lieven Annemans,Roy Remmen,Meredith B. Rosenthal,Walter Sermeus +5 more
TL;DR: One hundred twenty-eight evaluation studies provide a large body of evidence concerning the effects of P4P on clinical effectiveness and equity of care, however, less evidence on the impact on coordination, continuity, patient-centeredness and cost-effectiveness was found.
Journal ArticleDOI
An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviours and patient outcomes
TL;DR: An overview of systematic reviews that evaluates the impact of financial incentives on healthcare professional behaviour and patient outcomes found that financial incentives may be effective in changing healthcare professional practice.
Journal ArticleDOI
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
Jakub Adamski,Brian Godman,Brian Godman,Brian Godman,Gabriella Ofierska-Sujkowska,Bogusława Osińska,Harald Herholz,Kamila Wendykowska,Ott Laius,Saira Jan,Catherine Sermet,Corrine Zara,Marija Kalaba,Roland Gustafsson,Kristina Garuoliene,Alan Haycox,Silvio Garattini,Lars L. Gustafsson +17 more
TL;DR: There are only a limited number of situations where 'risk sharing' schemes should be considered as well as factors thatShould be considered by payers in advance of implementation, and whether systematic evaluations have been built into proposed schemes.
Journal ArticleDOI
The 'Wise List' - A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm
Lars L. Gustafsson,Björn Wettermark,Björn Wettermark,Brian Godman,Eva Andersén-Karlsson,Ulf Bergman,Jan Hasselström,Lars-Olof Hensjö,Paul Hjemdahl,Ingrid Jägre,Margaretha Julander,Bo Ringertz,Daniel Schmidt,Susan Sjöberg,Folke Sjöqvist,Carl-Olav Stiller,Elisabeth Törnqvist,Rolf Tryselius,Sigurd Vitols,Christer von Bahr +19 more
TL;DR: The acceptance of the 'Wise List' in terms of trust among physicians and among the public and increased adherence may be explained by clear criteria for drug recommendations, a comprehensive communication strategy, electronic access to recommendations, continuous medical education and involvement of professional networks and patients.
Journal ArticleDOI
Implementation strategies for health systems in low-income countries: an overview of systematic reviews
Tomas Pantoja,Newton Opiyo,Simon Lewin,Simon Lewin,Elizabeth J Paulsen,Agustín Ciapponi,Charles Shey Wiysonge,Charles Shey Wiysonge,Cristian A Herrera,Gabriel Rada,Blanca Peñaloza,Lilian Dudley,Marie-Pierre Gagnon,Sebastián García Martí,Andrew D Oxman +14 more
TL;DR: This overview provides an overview of the available evidence from up‐to‐date systematic reviews about the effects of implementation strategies for health systems in low‐income countries and finds the following interventions to have desirable effects on at least one outcome with moderate‐ or high‐certainty evidence.
References
More filters
Journal Article
Pharmaceutical management in ProCare Health Limited.
L Malcolm,M Barry,I MacLean +2 more
TL;DR: The most important finding is that general practitioners (GPs), working collaboratively, can establish a strategy of clinical and corporate governance which may be exerting a wide ranging influence over clinical behaviour.
Journal ArticleDOI
Variations in general practice prescribing: a multilevel model approach to determine the impact of practice characteristics, including fundholding and training status
Guy Houghton,Mark S. Gihhorpe +1 more
TL;DR: There are marked downward shifts in both the number of items prescribed and overall monthly expenditure occurring with every new wave of fundholding, which raises doubts about the efficacy of the transition to fundholding and the impact of such large changes upon patient care.
Journal ArticleDOI
The Effects of Physicians' Financial Incentives on the Effectiveness of Taiwan's Outpatient Drug Copayment Policy
TL;DR: The results indicate that total drug costs increase after the implementation of the co-payment policy and hospitals with physician fee programs that include drug revenue have longer duration per prescription and higher drug items per prescription.